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Mebendazole treatment of 
dracunculiasis 
Jean-Philippe Chippaux' Centre ORSTOM de 
Cotonou et Centre OCCGE de Cotonou, République du 
Bénin 
MULLER,(1979) claimed that no alteration of the 
adult Dracunculus medinensis or its larvae was seen 
after benzimidazole treatment. Further trials estab- 
lished that several benzimidazole drugs reduced the 
inflammation and lessened the duration of disabilities. 
Mebendazole was used by KALE (1975) in a dose of 
400 mg daily for 5 d, and by PAUL et al. (1983) in a 
daily dose of 1000 mg for 10 d. Both studies showed 
that mebendazole promoted rapid healing of worm 
emergence ulcers, induced earlier expulsion or easier 
manual extraction of worm, and prevented clinical 
relapse, However, the authors agreed that mebenda- 
zole had only moderate efficacy but was fairly well 
tolerated. The proposal to schedule mebendazole in 
primary health drug lists for villages in areas of Bénin 
with endemic dracunculiasis prompted this field trial. 
The trial was carried out in 4 villages of the central 
part of Bénin, consisting of about 200 people each. 
The villages were surveyed for 4 years to obtain 
epidemiological data; the average incidence of dracun- 
culiasis was 31%, 35%, 20% and 12% respectively. 
During the first year no treatment was given to 
villagers except for management of wounds. In the 
second year and &er, antibiotics and anti-inflamma- 
tory drugs were adminstered when necessary. The 
trial took place insthe third and fourth years. Patients 
were allocated to 2 groups. The &st group (iG.7 
patients) received 400 mg mebendazole daily for 5 d 
every week during the entire duration of their disease; 
the dosage was not adjusted for age or weight. The 
second group (613 patients) received normal suppor- 
uve treatment without mebendazole. 
Weekly follow-up was conducted during the entire 
transmission season (September-May). At each ex- 
amination, everyone in the trial was asked to complete 
a questionnaire recording duration of disease and 
disability, number of worms, location of emergence, 
and number of non-emerged worms. The diagnosis of 
a non-emerged worm was made on the presence of 
non-traumatic oedema or worm migration trails under 
the skin. 
Neither disease duration nor disability duration 
were significantly different between the 2 groups 
(P>0*05; Table 1). Non-emerged worms were much 
'Present address: Centre Pasteur du Cameroun, B.P. 1274, 
Yaoundé, Cameroun. 
Table 1. Duration of disease and disability after mebendazole 
treatment of dracunculiasis 
No. of non- 
No. of Duration of Duration of emerged 
cases dixlx (d) disability (d) worms 
Treated 107 128 40 45 (42.1%) 
Control 613 103 32 37 (60%) 
Value of Student's I - 0.34 0 1 2  10.82 
Table 2. Distribution of site of emergence of D. medioensis 
No. of worms Lower Upper Abdomen 
emerging Limbs limbs to head 
Treated 406 319 (785%) 51 (12.6%) 36 (8.9%) 
Control 1463 1289 (88.1%) 98 (6.7%) 76 (5.2%) 
more common in the treated group (P<O*OOOOl; 
Table 1). The site of emergence was significantly 
different between the 2 groups (x2=24*21, 2 degrees 
of freedom, P<O*OOOl; Table 2). 
The difference observed between the 2 groups 
could be explained by behavioural disorders induced 
by the high dose of mebendazole used in this trial. 
Adverse effects have never been described following a 
single dose of mebendazole. The diagnosis of non- 
emerged worms could be considered as subjective, 
but the emergence of the worm is obvious. The 
migration of the worms, resulting in the unusual 
pattern of emergence, could endanger the patient, as 
the Dracunculus female can expel embryos into any 
internal cavity such as joints. 
The benefits of mebendazole treatment therefore 
cannot offset its complications. Following PAUL er al. 
(1983), mebendazole is not recommended in mass 
treatment of dracunculiasis, and such therapy should 
be disoouïaged. 
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